The introduction of monoclonal antibodies (mAbs), such as the anti-human epidermal growth factor receptor 2 (HER2)/neu mAb Trastuzumab and the CD20 mAb Rituximab, has improved treatment options for patients with HER2-positive breast cancer and B cell malignancies, respectively [12, 13]. This evidence concerns the gene ERBB2 and breast cancer.